NVCR

SEC source: 0001562180-24-004749 · primarydocument.xml · derivative · entry 2

HILLEMAN JERYL L · CIK 0001216628 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 6,229

Underlying: Ordinary Shares · 6,229 shares

Expires 2034-06-04

F2 · derivative.exercise_date: Options to buy 6,229 ordinary shares will fully vest and become exercisable on the earlier of the following dates: (i) the first anniversary of the grant date or (ii) the day immediately preceding the Company's 2025 annual general meeting of shareholders.

SEC source: 0001562180-24-004749 · primarydocument.xml · nonDerivative · entry 1

HILLEMAN JERYL L · CIK 0001216628 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 6,590

F1 · shares: These restricted stock units are scheduled to vest 100% on the earlier of the following dates: (i) the first anniversary of the grant date or (ii) the day immediately preceding the Company's 2025 annual general meeting of shareholders.

SEC source: 0001562180-24-004824 · primarydocument.xml · derivative · entry 3

GROENHUYSEN WILHELMUS CM · CIK 0001264783 · Chief Operating Officer

10b5-1 filing: No plan indicated

Ownership: Indirect · The 2020 Groenhuysen Annuity Trust

Disclosed balance after: 95,000

Underlying: Ordinary Shares · 124,373 shares

Expires 2027-02-21

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · derivative.exercise_date: Options to buy 219,372 ordinary shares will vest in equal installments on each of February 22, 2018, 2019 and 2020, subject to the reporting person's continued employment through such dates.

F2 · ownership.nature: By The 2020 Groenhuysen Annuity Trust. Mr. Groenhuysen does not disclaim beneficial ownership.

SEC source: 0001562180-24-004824 · primarydocument.xml · nonDerivative · entry 1

GROENHUYSEN WILHELMUS CM · CIK 0001264783 · Chief Operating Officer

10b5-1 filing: No plan indicated

Ownership: Indirect · The 2020 Groenhuysen Annuity Trust

Disclosed balance after: 124,373

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

SEC source: 0001562180-24-004761 · primarydocument.xml · nonDerivative · entry 1

VERNON W ANTHONY · CIK 0001369091 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 164,833

F1 · price: This transaction was executed in multiple trades at prices ranging from $23.78 USD to $24.00 USD; the price reported above reflects the weighted average sale price.

SEC source: 0001562180-24-004759 · primarydocument.xml · nonDerivative · entry 1

Scannell Timothy J · CIK 0001451533 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 2,964

F1 · price: This transaction was executed in multiple trades at prices ranging from $23.80 USD to $23.95 USD; the price reported above reflects the weighted average sale price.

SEC source: 0001562180-24-004758 · primarydocument.xml · nonDerivative · entry 1

LEUNG GABRIEL · CIK 0001236183 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 78,175

F1 · price: This transaction was executed in multiple trades at prices ranging from $23.75 USD to $24.00 USD; the price reported above reflects the weighted average sale price.

SEC source: 0001562180-24-002248 · primarydocument.xml · nonDerivative · entry 2

GROENHUYSEN WILHELMUS CM · CIK 0001264783 · Chief Operating Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 251,235

F1 · shares: Represents the number of shares required to be sold by the reporting person to cover tax withholding obligations in connection with the vesting of Restricted Stock Units. This sale is mandated by the issuer's award agreement under its equity incentive plans to require the satisfaction of tax withholding obligations to be funded by a "sell to cover" transaction and does not represent a discretionary trade by the reporting person.

SEC source: 0001562180-24-002247 · primarydocument.xml · nonDerivative · entry 2

Leonard Frank X · CIK 0001822879 · EVP, Pres., Novocure Oncology

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 160,098

F1 · shares: Represents the number of shares required to be sold by the reporting person to cover tax withholding obligations in connection with the vesting of Restricted Stock Units. This sale is mandated by the issuer's award agreement under its equity incentive plans to require the satisfaction of tax withholding obligations to be funded by a "sell to cover" transaction and does not represent a discretionary trade by the reporting person.

SEC source: 0001562180-24-002248 · primarydocument.xml · nonDerivative · entry 1

GROENHUYSEN WILHELMUS CM · CIK 0001264783 · Chief Operating Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 252,452

F1 · shares: Represents the number of shares required to be sold by the reporting person to cover tax withholding obligations in connection with the vesting of Restricted Stock Units. This sale is mandated by the issuer's award agreement under its equity incentive plans to require the satisfaction of tax withholding obligations to be funded by a "sell to cover" transaction and does not represent a discretionary trade by the reporting person.

SEC source: 0001562180-24-002247 · primarydocument.xml · nonDerivative · entry 1

Leonard Frank X · CIK 0001822879 · EVP, Pres., Novocure Oncology

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 160,938

F1 · shares: Represents the number of shares required to be sold by the reporting person to cover tax withholding obligations in connection with the vesting of Restricted Stock Units. This sale is mandated by the issuer's award agreement under its equity incentive plans to require the satisfaction of tax withholding obligations to be funded by a "sell to cover" transaction and does not represent a discretionary trade by the reporting person.

SEC source: 0001562180-24-001988 · primarydocument.xml · nonDerivative · entry 2

Leonard Frank X · CIK 0001822879 · EVP, Pres., Novocure Oncology

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 162,617

F2 · shares: Represents the number of shares required to be sold by the reporting person to cover tax withholding obligations in connection with the vesting of Restricted Stock Units. This sale is mandated by the issuer's award agreement under its equity incentive plans to require the satisfaction of tax withholding obligations to be funded by a "sell to cover" transaction and does not represent a discretionary trade by the reporting person.

SEC source: 0001562180-24-001980 · primarydocument.xml · nonDerivative · entry 3

GROENHUYSEN WILHELMUS CM · CIK 0001264783 · Chief Operating Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 254,559

F4 · shares: Represents the number of shares required to be sold by the reporting person to cover tax withholding obligations in connection with the vesting of Restricted Stock Units. This sale is mandated by the issuer's award agreement under its equity incentive plans to require the satisfaction of tax withholding obligations to be funded by a "sell to cover" transaction and does not represent a discretionary trade by the reporting person.

SEC source: 0001562180-24-001984 · primarydocument.xml · derivative · entry 2

Giladi Moshe · CIK 0002001639 · Chief Science Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 78,174

Underlying: Ordinary Shares · 78,174 shares

Expires 2034-02-26

F2 · derivative.exercise_date: Options to buy 78,174 ordinary shares will vest in equal installments on each of February 27, 2025, 2026, 2027 and 2028, subject to the reporting person's continued employment through such dates.

SEC source: 0001562180-24-001984 · primarydocument.xml · nonDerivative · entry 1

Giladi Moshe · CIK 0002001639 · Chief Science Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 69,771

F1 · shares: Represents restricted share units that are scheduled to vest in equal installments on February 27, 2025, 2026 and 2027, subject to the reporting person's continued employment through such dates.

SEC source: 0001562180-24-001986 · primarydocument.xml · derivative · entry 2

Weinberg Uri · CIK 0001811030 · Chief Innovation Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 125,078

Underlying: Ordinary Shares · 125,078 shares

Expires 2034-02-26

F2 · derivative.exercise_date: Options to buy 125,078 ordinary shares will vest in equal installments on each of February 27, 2025, 2026, 2027 and 2028, subject to the reporting person's continued employment through such dates.

SEC source: 0001562180-24-001986 · primarydocument.xml · nonDerivative · entry 1

Weinberg Uri · CIK 0001811030 · Chief Innovation Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 171,148

F1 · shares: Represents restricted share units that are scheduled to vest in equal installments on February 27, 2025, 2026 and 2027, subject to the reporting person's continued employment through such dates.

SEC source: 0001562180-24-001989 · primarydocument.xml · derivative · entry 2

Cordova Ashley · CIK 0001822014 · Chief Financial Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 156,348

Underlying: Ordinary Shares · 156,348 shares

Expires 2034-02-26

F2 · derivative.exercise_date: Options to buy 156,348 ordinary shares will vest in equal installments on each of February 27, 2025, 2026, 2027 and 2028, subject to the reporting person's continued employment through such dates.

SEC source: 0001562180-24-001989 · primarydocument.xml · nonDerivative · entry 1

Cordova Ashley · CIK 0001822014 · Chief Financial Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 219,867

F1 · shares: Represents restricted share units that are scheduled to vest in equal installments on February 27, 2025, 2026 and 2027, subject to the reporting person's continued employment through such dates.

SEC source: 0001562180-24-001988 · primarydocument.xml · derivative · entry 3

Leonard Frank X · CIK 0001822879 · EVP, Pres., Novocure Oncology

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 156,348

Underlying: Ordinary Shares · 156,348 shares

Expires 2034-02-26

F3 · derivative.exercise_date: Options to buy 156,348 ordinary shares will vest in equal installments on each of February 27, 2025, 2026, 2027 and 2028, subject to the reporting person's continued employment through such dates.

SEC source: 0001562180-24-001988 · primarydocument.xml · nonDerivative · entry 1

Leonard Frank X · CIK 0001822879 · EVP, Pres., Novocure Oncology

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 164,695

F1 · shares: Represents restricted share units that are scheduled to vest in equal installments on February 27, 2025, 2026 and 2027, subject to the reporting person's continued employment through such dates.

SEC source: 0001562180-24-001987 · primarydocument.xml · derivative · entry 2

Puri Michal Nath · CIK 0001997032 · Chief Human Resources Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 109,443

Underlying: Ordinary Shares · 109,443 shares

Expires 2034-02-26

F2 · derivative.exercise_date: Options to buy 109,443 ordinary shares will vest in equal installments on each of February 27, 2025, 2026, 2027 and 2028, subject to the reporting person's continued employment through such dates.

SEC source: 0001562180-24-001987 · primarydocument.xml · nonDerivative · entry 1

Puri Michal Nath · CIK 0001997032 · Chief Human Resources Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 109,167

F1 · shares: Represents restricted share units that are scheduled to vest in equal installments on February 27, 2025, 2026 and 2027, subject to the reporting person's continued employment through such dates.

SEC source: 0001562180-24-001985 · primarydocument.xml · derivative · entry 2

Leupin Nicolas · CIK 0002007766 · Chief Medical Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 78,174

Underlying: Ordinary Shares · 78,174 shares

Expires 2034-02-26

F2 · derivative.exercise_date: Options to buy 78,174 ordinary shares will vest in equal installments on each of February 27, 2025, 2026, 2027 and 2028, subject to the reporting person's continued employment through such dates.

SEC source: 0001562180-24-001985 · primarydocument.xml · nonDerivative · entry 1

Leupin Nicolas · CIK 0002007766 · Chief Medical Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 51,124

F1 · shares: Represents restricted share units that are scheduled to vest in equal installments on February 27, 2025, 2026 and 2027, subject to the reporting person's continued employment through such dates.

SEC source: 0001562180-24-001982 · primarydocument.xml · derivative · entry 3

Ben Arye Barak · CIK 0001917165 · General Counsel

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 125,078

Underlying: Ordinary Shares · 125,078 shares

Expires 2034-02-26

F4 · derivative.exercise_date: Options to buy 125,078 ordinary shares will vest in equal installments on each of February 27, 2025, 2026, 2027 and 2028, subject to the reporting person's continued employment through such dates.

SEC source: 0001562180-24-001982 · primarydocument.xml · nonDerivative · entry 2

Ben Arye Barak · CIK 0001917165 · General Counsel

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 117,122

F3 · shares: Represents restricted share units that are scheduled to vest in equal installments on February 27, 2025, 2026 and 2027, subject to the reporting person's continued employment through such dates.

SEC source: 0001562180-24-001980 · primarydocument.xml · derivative · entry 4

GROENHUYSEN WILHELMUS CM · CIK 0001264783 · Chief Operating Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 71,920

Underlying: Ordinary Shares · 71,920 shares

Expires 2034-02-26

F5 · derivative.exercise_date: Options to buy 71,920 ordinary shares will vest in equal installments on each of February 27, 2025, 2026, 2027 and 2028, subject to the reporting person's continued employment through such dates.

SEC source: 0001562180-24-001980 · primarydocument.xml · nonDerivative · entry 2

GROENHUYSEN WILHELMUS CM · CIK 0001264783 · Chief Operating Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 256,862

F3 · shares: Represents restricted share units that are scheduled to vest in equal installments on February 27, 2025, 2026 and 2027, subject to the reporting person's continued employment through such dates.

SEC source: 0001562180-24-001982 · primarydocument.xml · nonDerivative · entry 1

Ben Arye Barak · CIK 0001917165 · General Counsel

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 35,323

F1 · security: The reporting person is voluntarily reporting the acquisition of shares of the issuer's ordinary shares pursuant to the NovoCure Limited Employee Share Purchase Plan ("ESPP"), for the ESPP purchase period of July 1, 2023 through December 31, 2023. This transaction is also exempt under Rule 16b-3(c).

F2 · price: In accordance with the ESPP, these shares were purchased based on 85% of the closing price of the issuer's ordinary shares on December 31, 2023.

SEC source: 0001562180-24-001980 · primarydocument.xml · nonDerivative · entry 1

GROENHUYSEN WILHELMUS CM · CIK 0001264783 · Chief Operating Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 209,828

F1 · security: The reporting person is voluntarily reporting the acquisition of shares of the issuer's ordinary shares pursuant to the NovoCure Limited Employee Share Purchase Plan ("ESPP"), for the ESPP purchase period of July 1, 2023 through December 31, 2023. This transaction is also exempt under Rule 16b-3(c).

F2 · price: In accordance with the ESPP, these shares were purchased based on 85% of the closing price of the issuer's ordinary shares on December 31, 2023.

SEC source: 0001562180-23-007594 · primarydocument.xml · nonDerivative · entry 1

Shah Pritesh · CIK 0001744884 · Chief Growth Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 124,511

F1 · shares: Transaction was made pursuant to a Rule 10b5-1 trading plan adopted by Mr. Shah.

SEC source: 0001562180-23-007502 · primarydocument.xml · derivative · entry 8

Cordova Ashley · CIK 0001822014 · Chief Financial Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 0

Underlying: Ordinary Shares · 175 shares

Expires 2026-02-24

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · derivative.exercise_date: Vests 2,686 share(s) on 24-Feb-2019, 6,250 share(s) on 24-Feb-2020

SEC source: 0001562180-23-007502 · primarydocument.xml · nonDerivative · entry 4

Cordova Ashley · CIK 0001822014 · Chief Financial Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 117,618

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

SEC source: 0001562180-23-007502 · primarydocument.xml · derivative · entry 7

Cordova Ashley · CIK 0001822014 · Chief Financial Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 0

Underlying: Ordinary Shares · 7,752 shares

Expires 2027-02-21

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F2 · derivative.exercise_date: Vests 2 share(s) on 22-Feb-2018, 9,750 share(s) on 22-Feb-2021

SEC source: 0001562180-23-007502 · primarydocument.xml · derivative · entry 6

Cordova Ashley · CIK 0001822014 · Chief Financial Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 0

Underlying: Ordinary Shares · 2,480 shares

Expires 2026-07-27

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

SEC source: 0001562180-23-007502 · primarydocument.xml · derivative · entry 5

Cordova Ashley · CIK 0001822014 · Chief Financial Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 175

Underlying: Ordinary Shares · 7,561 shares

Expires 2026-02-24

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · derivative.exercise_date: Vests 2,686 share(s) on 24-Feb-2019, 6,250 share(s) on 24-Feb-2020

SEC source: 0001562180-23-007502 · primarydocument.xml · nonDerivative · entry 3

Cordova Ashley · CIK 0001822014 · Chief Financial Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 117,443

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

SEC source: 0001562180-23-007502 · primarydocument.xml · nonDerivative · entry 2

Cordova Ashley · CIK 0001822014 · Chief Financial Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 109,691

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

SEC source: 0001562180-23-007502 · primarydocument.xml · nonDerivative · entry 1

Cordova Ashley · CIK 0001822014 · Chief Financial Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 107,211

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

SEC source: 0001562180-23-007549 · primarydocument.xml · derivative · entry 2

Puri Michal Nath · CIK 0001997032 · Chief Human Resources Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 57,604

Underlying: Ordinary Shares · 57,604 shares

Expires 2033-10-30

F2 · derivative.exercise_date: These stock options will vest in equal parts on the first, second, third and fourth anniversary of the grant date.

SEC source: 0001562180-23-007549 · primarydocument.xml · nonDerivative · entry 1

Puri Michal Nath · CIK 0001997032 · Chief Human Resources Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 37,593

F1 · shares: Represents restricted share units that are scheduled to vest in equal parts on the first, second and third anniversary of the grant date, subject to the reporting person's continued employment through such dates.

SEC source: 0001562180-23-006686 · primarydocument.xml · nonDerivative · entry 1

Cordova Ashley · CIK 0001822014 · Chief Financial Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 99,650

F1 · shares: Represents the number of shares required to be sold by the reporting person to cover tax withholding obligations in connection with the vesting of Restricted Stock Units. This sale is mandated by the issuer's award agreement under its equity incentive plans to require the satisfaction of tax withholding obligations to be funded by a "sell to cover" transaction and does not represent a discretionary trade by the reporting person.

SEC source: 0001562180-23-006683 · primarydocument.xml · nonDerivative · entry 1

GROENHUYSEN WILHELMUS CM · CIK 0001264783 · Chief Operating Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 209,825

F1 · shares: Represents the number of shares required to be sold by the reporting person to cover tax withholding obligations in connection with the vesting of Restricted Stock Units. This sale is mandated by the issuer's award agreement under its equity incentive plans to require the satisfaction of tax withholding obligations to be funded by a "sell to cover" transaction and does not represent a discretionary trade by the reporting person.

SEC source: 0001562180-23-006680 · primarydocument.xml · nonDerivative · entry 1

Shah Pritesh · CIK 0001744884 · Chief Growth Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 124,893

F1 · shares: Represents the number of shares required to be sold by the reporting person to cover tax withholding obligations in connection with the vesting of Restricted Stock Units. This sale is mandated by the issuer's award agreement under its equity incentive plans to require the satisfaction of tax withholding obligations to be funded by a "sell to cover" transaction and does not represent a discretionary trade by the reporting person.

SEC source: 0001562180-23-006182 · primarydocument.xml · nonDerivative · entry 1

Cordova Ashley · CIK 0001822014 · Chief Financial Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 100,533

F1 · shares: Represents the number of shares required to be sold by the reporting person to cover tax withholding obligations in connection with the vesting of Restricted Stock Units. This sale is mandated by the issuer's award agreement under its equity incentive plans to require the satisfaction of tax withholding obligations to be funded by a "sell to cover" transaction and does not represent a discretionary trade by the reporting person.

SEC source: 0001562180-23-005759 · primarydocument.xml · nonDerivative · entry 1

Burke William Patrick · CIK 0001880493 · Chief Human Resources Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 66,447

F1 · security: The reporting person is voluntarily reporting the acquisition of shares of the issuer's ordinary shares pursuant to the NovoCure Limited Employee Share Purchase Plan ("ESPP"), for the ESPP purchase period of January1, 2023 through June 30, 2023. This transaction is also exempt under Rule 16b-3(c).

F2 · price: In accordance with the ESPP, these shares were purchased based on 85% of the closing price of the issuer's ordinary shares on June 30, 2023.

SEC source: 0001562180-23-005762 · primarydocument.xml · nonDerivative · entry 1

Weinberg Uri · CIK 0001811030 · Chief Innovation Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 89,349

F1 · security: The reporting person is voluntarily reporting the acquisition of shares of the issuer's ordinary shares pursuant to the NovoCure Limited Employee Share Purchase Plan ("ESPP"), for the ESPP purchase period of January1, 2023 through June 30, 2023. This transaction is also exempt under Rule 16b-3(c).

F2 · price: In accordance with the ESPP, these shares were purchased based on 85% of the closing price of the issuer's ordinary shares on June 30, 2023.

SEC source: 0001562180-23-005761 · primarydocument.xml · nonDerivative · entry 1

GROENHUYSEN WILHELMUS CM · CIK 0001264783 · Chief Operating Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 210,119

F1 · security: The reporting person is voluntarily reporting the acquisition of shares of the issuer's ordinary shares pursuant to the NovoCure Limited Employee Share Purchase Plan ("ESPP"), for the ESPP purchase period of January1, 2023 through June 30, 2023. This transaction is also exempt under Rule 16b-3(c).

F2 · price: In accordance with the ESPP, these shares were purchased based on 85% of the closing price of the issuer's ordinary shares on June 30, 2023.

SEC source: 0001562180-23-005760 · primarydocument.xml · nonDerivative · entry 1

Shah Pritesh · CIK 0001744884 · Chief Growth Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 125,166

F1 · security: The reporting person is voluntarily reporting the acquisition of shares of the issuer's ordinary shares pursuant to the NovoCure Limited Employee Share Purchase Plan ("ESPP"), for the ESPP purchase period of January1, 2023 through June 30, 2023. This transaction is also exempt under Rule 16b-3(c).

F2 · price: In accordance with the ESPP, these shares were purchased based on 85% of the closing price of the issuer's ordinary shares on June 30, 2023.